RCUS — Arcus Biosciences Inc
NYSE · Healthcare · Biotechnology
$29.71
+$0.43 (+1.47%)
Arcus Biosciences Inc (RCUS) is a biotechnology company listed on NYSE. It is led by Terry J. Rosen Ph.D., based in 3928 Point Eden Way, Hayward, CA, United States, 94545, with about 627 employees. Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; and Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer; Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in phase 2 clinical trial for colorectal cancer; and Zimberelimab, an anti-PD-1 antibody. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer; and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.
Latest reported RCUS revenue for 2025-09-30 was $26.0M. Net income was -$247.0M. Revenue was down 83.8% from 2025-06-30 to 2025-09-30. RCUS currently screens at market cap $885.2M.
Use this RCUS page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the RCUS quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the RCUS SEC filings page. Lician reads the product cache first so this HTML stays unique to Arcus Biosciences Inc even when a live quote feed is slow.
About Arcus Biosciences Inc
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; and Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer; Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in phase 2 clinical trial for colorectal cancer; and Zimberelimab, an anti-PD-1 antibody. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer; and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.
RCUS Key Statistics
Market Cap
$885.20M
Volume
655,462
Previous Close
$30.12
Day Range
$30.11 – $31.58
EPS
-$3.14
Revenue
$258.00M
Net Income
-$283.00M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
+120.5%
Profit Margin
-109.7%
Employees
627
RCUS Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $258.00M | $117.00M | $112.00M | $383.00M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$283.00M | -$307.00M | -$267.00M | $53.00M |
| EPS (Diluted) | -$3.14 | -$4.15 | -$3.71 | $0.71 |
Total Assets
$1.15B
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$150.00M
Operating Cash Flow
-$170.00M
Free Cash Flow
$0.00
Arcus Biosciences Inc Company Information
- Co-Founder, Chairman & CEO
- Terry J. Rosen Ph.D.
- Headquarters
- 3928 Point Eden Way, Hayward, CA, United States, 94545
- Website
- www.arcusbio.com
- Phone
- 510 694 6200
- IPO / Founded
- 2018-03-15
- Sector
- Healthcare
- Industry
- Biotechnology